Innocenti Receives R21 Grant to Personalize Angiogenesis Inhibitors to Individual Cancer Patients

Angiogenesis inhibitors are a class of drugs commonly used in cancer therapy. However, there isn’t a way to identify patients who will benefit the most from treatment with these drugs. A new $275,000 grant could help Federico Innocenti, MD, PhD, and his team identify such patients based on their genetic profile.

Innocenti Receives R21 Grant to Personalize Angiogenesis Inhibitors to Individual Cancer Patients click to enlarge Federico Innocenti, MD, PhD

Angiogenesis is the formation of new blood vessels that promote tumor growth Innocenti was awarded a two-year R21 grant from the National Institutes of Health and National Cancer Institute. R21 awards are given to encourage early-stage, high risk-high reward research. Nancy DeMore, MD, will collaborate with Innocenti on this project.